Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma, IDH-wildtype: early-phase trial registry
12 of 16 indexed Glioblastoma, IDH-wildtype trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 12 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Glioblastoma, IDH-wildtype: 16 US clinical trials tracked, 12 recruiting.
Glioblastoma, IDH-wildtype is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Jasper Gerritsen, running 4 of these trials.
Enrollment posture brief
Registry condition glioblastoma-idh-wildtype
OPEN 12 | RECR 75% | LATE 1 | EARLY 9 | RANK #1060 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Glioblastoma, IDH-wildtype lists 12 open slots (75% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma, IDH-wildtype on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma, IDH-wildtype is recruiting above its size-band peers.
12 of 16 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Glioblastoma, IDH-wildtype research.
Jasper Gerritsen accounts for 4 of 16 trials (25%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Glioblastoma, IDH-wildtype enrolment sits around 116 participants.
Median target enrolment is 116 among the 16 trials that report a genuine target (sentinel values excluded). 7 of those (43.8%) plan for fewer than 100 participants.
-
Glioblastoma, IDH-wildtype splits between interventional and observational designs.
11 interventional and 5 observational studies make up this index (68.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Jasper Gerritsen
NCT06146738
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Jasper Gerritsen
NCT06118723
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Jasper Gerritsen
NCT06146725
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Jasper Gerritsen
NCT06283927
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
NCT06273176
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Mayo Clinic
NCT07091864
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
ECOG-ACRIN Cancer Research Group
NCT06319027
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics
NCT05879367
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT05879250
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
NCT07223034
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
NCT05236036
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT04528680
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
NCT04197934
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
NCT04145115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma, IDH-wildtype records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma, IDH-wildtype trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma, IDH-wildtype page
16 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Glioblastoma, IDH-wildtype trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jasper Gerritsen sponsors the most Glioblastoma, IDH-wildtype trials on record, review their full trial history before evaluating a specific study. See Jasper Gerritsen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma, IDH-wildtype condition card totals 16 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.